NASDAQ$BBIO
Bridgebio Pharma Inc · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
BridgeBio reported financial results for Q4 and full year 2020 and provided a business update.
BridgeBio Pharma reported its Q4 and full year 2020 financial results, highlighting the completion of the Eidos Therapeutics acquisition and progress in clinical trials. The company ended the quarter with $607.1 million in cash, cash equivalents, and marketable securities.
- Completed acquisition of Eidos Therapeutics, allowing BridgeBio to deploy its clinical and commercial infrastructure for acoramidis.
- The FDA accepted the NDA for infigratinib for cholangiocarcinoma under Priority Review and the RTOR pilot program.
- Initiated two new clinical trials and progressed 17 ongoing clinical trials.
- Ended the quarter with $607.1 million in cash, cash equivalents, and marketable securities.
Headline financials
Revenue & EPS history
Bridgebio · Revenue · Quarterly
$122K
Revenue by segment
Bridgebio · $100K total across 1 segment · Q2 2023
- License and Services Revenue$100K—100.0%
Forward guidance
BridgeBio anticipates several major milestones in 2021 or early 2022 for its four core value drivers, with topline results expected for Acoramidis and initial data for Encaleret, low-dose Infigratinib, and BBP-631.
Tailwinds
- Topline results from Part A of the ATTRibute-CM trial for Acoramidis are expected in late 2021 or early 2022.
- Early results from an ongoing Phase 2 proof-of-concept study for Encaleret will be shared at the Endocrine Society’s 2021 Annual Meeting on March 20th.
- Initial data from the ongoing Phase 2 dose ranging study for low-dose Infigratinib are expected in the second half of 2021.
- Initiation of a first-in-human Phase 1/2 study for BBP-631 is expected in the second half of 2021, with initial data anticipated in late 2021 or early 2022.
- The company expects current cash, cash equivalents and marketable securities to support its planned operations into 2023.
Headwinds
- The unknown future impact of the COVID-19 pandemic delay on certain clinical trial milestones and/or our operations or operating expenses.
- Uncertainty of the expected financial performance of each of us and Eidos following completion of the merger, including the possibility that the expected synergies and value creation from the merger will not be realized or will not be realized within the expected time period.
- Despite having ongoing interactions with the FDA or other regulatory agencies, the FDA or such other regulatory agencies may not agree with our regulatory approval strategies, components of our filings, such as clinical trial designs, conduct and methodologies, or the sufficiency of data submitted.
- Potential adverse impacts due to the global COVID-19 pandemic such as delays in regulatory review, manufacturing and supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy.
- Success of clinical trials, regulatory filings, approvals and/or sales
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2020
+1.5%
Avg return
Earnings day
+0.6%
Avg return
5 days after
+4.3%
Avg return
30 days after
48%
13 / 27 earnings
Positive
+40.9%
Q2 2022
Best reaction
-21.9%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.0% | -3.2% | -0.7% | |
| Q4 2025 | -2.8% | -4.1% | +2.0% | |
| Q3 2025 | -4.9% | -7.9% | +8.1% | |
| Q1 2025 | +5.3% | +4.9% | -6.0% | |
| Q4 2024 | +1.4% | -5.3% | -4.2% | |
| Q3 2024 | -5.1% | -9.2% | +5.9% | |
| Q2 2024 | +0.9% | -4.2% | +7.3% | |
| Q1 2024 | +3.0% | +2.8% | +3.6% | |
| Q4 2023 | -0.5% | +4.6% | -13.4% | |
| Q3 2023 | +8.2% | +10.3% | +16.1% | |
| Q2 2023 | -2.3% | +0.8% | -4.4% | |
| Q1 2023 | -5.0% | -4.4% | -1.0% | |
| Q4 2022 | -4.7% | -6.6% | +21.8% | |
| Q3 2022 | -1.1% | -7.0% | -4.8% | |
| Q2 2022 | +40.9% | +39.7% | +26.7% | |
| Q1 2022 | -21.9% | -29.5% | -15.9% | |
| Q4 2021 | +7.6% | +13.9% | +41.1% | |
| Q3 2021 | +6.8% | +2.0% | -22.8% | |
| Q2 2021 | +2.4% | -1.1% | -2.3% | |
| Q1 2021 | -9.3% | -7.2% | +9.5% | |
| Q4 2020 | +4.9% | -1.8% | -9.8% | |
| Q3 2020 | -1.6% | +0.3% | +30.4% | |
| Q2 2020 | +1.4% | +0.2% | +16.2% | |
| Q1 2020 | -6.8% | +6.1% | -12.7% | |
| Q4 2019 | +2.2% | -9.3% | -21.3% | |
| Q3 2019 | +22.1% | +26.2% | +49.0% | |
| Q2 2019 | +0.0% | +4.8% | -3.2% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro